Halozyme Therapeutics announces licensing deal with Acumen Pharmaceuticals for Alzheimer’s therapy advancement
Halozyme Therapeutics, Inc. has entered a pivotal global collaboration and non-exclusive licensing agreement with Acumen Pharmaceuticals. This partnership focuses on utilizing Halozyme’s ENHANZE drug delivery technology to potentially transform the administration of Acumen’s Alzheimer’s treatment. Groundbreaking Approach to Alzheimer’s Treatment Administration The agreement details include an initial payment by Acumen to Halozyme, alongside the possibility […]